LabCorp buys National Genetics Institute:
This article was originally published in Clinica
Executive Summary
Laboratory Corporation of America (LabCorp) has agreed to buy all of the stock of National Genetics Institute, a privately held provider of molecular diagnostic hepatitis C (HCV) testing. Terms of the agreement, which is expected to close in July, were not disclosed. LabCorp says the deal with Los Angeles-based National Genetics will bring it ultra-sensitive tools to assess HCV disease progress at reviously undetectable levels. We believe infectious disease testing, and specifically hepatitis C testing employing molecular diagnostics, will continue to be one of the fastest growing areas of laboratory testing," said Thomas MacMahon, LabCorp's CEO.